Core Viewpoint - The company has entered into a strategic cooperation framework agreement with Huada Co-Win to establish an innovative drug intellectual property tokenization fund, aiming to enhance its business layout and role in reshaping the global medical innovation drug asset value chain [1][2] Group 1 - The company will collaborate with Huada Co-Win to create the IVD-BGICoWin fund, which will invest in projects under the NewCo+RWA Web3 exchange ecosystem [1] - The company or its designated entities will act as limited partners contributing to the fund, while Huada Co-Win will serve as the general partner responsible for managing the fund [1] - Huada Co-Win is a private equity fund management company with extensive experience and resources in the innovative medical and pharmaceutical sectors [1] Group 2 - The board believes that this strategic cooperation will advance the company's three-pronged strategy of "NewCo+RWA+stablecoin" to expand its business [2] - The board considers the framework agreement to be in the overall interest of the company and its shareholders [2]